Biotech Gainers: Arrowhead Research (NASDAQ:ARWR), DARA Biosciences (NASDAQ:DARA), Synthetic Biologics (NYSEMKT:SYN), Oncothyreon (NASDAQ:ONTY)
Equities research analysts at Deutsche Bank assumed coverage on shares of Arrowhead Research Corp (NASDAQ:ARWR) in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $45.00 price target on the stock. Arrowhead Research Corp (NASDAQ:ARWR) stock performance was 24.46% in last session and finished the day at $26.31. Traded volume was 7,684,553 million shares in the … Continue reading Biotech Gainers: Arrowhead Research (NASDAQ:ARWR), DARA Biosciences (NASDAQ:DARA), Synthetic Biologics (NYSEMKT:SYN), Oncothyreon (NASDAQ:ONTY)
Services Sector Gainers; Renren Inc (NYSE:RENN), DryShips Inc. (NASDAQ:DRYS), Lions Gate Entertainment (NYSE:LGF), AirMedia Group (NASDAQ:AMCN)
Renren Inc (NYSE:RENN) options set a new 90-day record for the number of contracts that exchanged hands between the buyers and the sellers on both the call and put side. Renren Inc (NYSE:RENN) stock performance was 22.56% in last session and finished the day at $4.78. Traded volume was 16.87million shares in the last session and the average volume of the stock remained 1.91million shares. … Continue reading Services Sector Gainers; Renren Inc (NYSE:RENN), DryShips Inc. (NASDAQ:DRYS), Lions Gate Entertainment (NYSE:LGF), AirMedia Group (NASDAQ:AMCN)
Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Peregrine Pharmaceuticals (NASDAQ:PPHM), MannKind Corporation (NASDAQ:MNKD), Synta Pharmaceuticals (NASDAQ:SNTA)
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has been trading with ups and downs since the past few days, after the company announced better-than-expected results and its plans to partner for its flagship drug Iclusig. One of the major takeaway during the earnings call is Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s CEO Harvey Berger’s indication for potential partnership in Japan for Iclusig, as the formal announcement is expected to come … Continue reading Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Peregrine Pharmaceuticals (NASDAQ:PPHM), MannKind Corporation (NASDAQ:MNKD), Synta Pharmaceuticals (NASDAQ:SNTA)
Stock Forecast: What Can We Expect From the Microsoft (NASDAQ MSFT) Stock
Microsoft (NASDAQ MSFT) remains a top technology stock in the market today. The stock has really performed well in the past three-four months, with analysts still expecting bigger and better things from the MSFT stock. Under the leadership of Satya Nadella, Microsoft has undergone a drastic change. The mobile and cloud first strategy has seemingly worked wonders for the Microsoft stock. In this article, we … Continue reading Stock Forecast: What Can We Expect From the Microsoft (NASDAQ MSFT) Stock
Stocks Making Noise After-Hours: Sanchez Energy (NYSE:SN), RigNet (NASDAQ:RNET), China New Borun Corp (NYSE:BORN)
Sanchez Energy (NYSE:SN) is higher in the after hours session after the company reported financial results for Q4 improved year-over-year, with record revenue growth, despite falling short of analysts’ expectations. Shares are up 1.22% at $29.90, with a 52-week range of $17.02 – $32.96. The independent oil and natural gas exploration and production company reported Q4 adjusted earnings of $0.27 per share, compared with the … Continue reading Stocks Making Noise After-Hours: Sanchez Energy (NYSE:SN), RigNet (NASDAQ:RNET), China New Borun Corp (NYSE:BORN)
NXP Semiconductors (NASDAQ:NXPI) Price Target Upped to $70 by Drexel Hamilton
In a research not issued on Wednesday, Drexel Hamilton increased their price target to $70 for NXP Semiconductors (NASDAQ:NXPI). Highlights from the report include: A broadening economic upturn providing global cyclical lift benefits well-situated NXP (NASDAQ:NXPI), especially in mobiles, autos, security and industrial Customers entering the year with moderate inventories are now faced with establishing buffer stocks that will benefit orders and build backlog Resulting … Continue reading NXP Semiconductors (NASDAQ:NXPI) Price Target Upped to $70 by Drexel Hamilton
